Erlotinib: all 574 studies that test it

Page 3 of 6. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell CancerTerminatedNCT00412217Phase 3Results posted
• BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00411632Phase 2Results posted
• Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck CancerCompletedNCT00410826Phase 2Results posted
• BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLCCompletedNCT00410059Phase 2Results posted
• Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung CancerCompletedNCT00408499Phase 1/2Results posted
• Erlotinib Prevention of Oral Cancer (EPOC)CompletedNCT00402779Phase 3Results posted
• Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal CancerCompletedNCT00393068Phase 2Results posted
• Treatment of Head & Neck Cancer With Chemotherapy and RadiationCompletedNCT00392704Phase 2Results posted
• Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the LungTerminatedNCT00391586Phase 2Results posted
• Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsCompletedNCT00390429Phase 1/2Results posted
• Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaTerminatedNCT00387894Phase 2Results posted
• Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung CancerCompletedNCT00385996Phase 2Results posted
• Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder CancerCompletedNCT00380029Phase 2Results posted
• Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00376948Phase 2Results posted
• A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive TumorsCompletedNCT00373425Phase 3Results posted
• A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell CarcinomaCompletedNCT00369512Phase 2Results posted
• Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung CancerCompletedNCT00367601Phase 2Results posted
• Gemcitabine, Bevacizumab and Erlotinib in Pancreatic CancerCompletedNCT00366457Phase 2Results posted
• Bevacizumab and Erlotinib in Treating Patients With Advanced Liver CancerCompletedNCT00365391Phase 2Results posted
• Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With GemcitabineCompletedNCT00365144Phase 2Results posted
• Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary SiteCompletedNCT00360360Phase 2Results posted
• Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary TumorsCompletedNCT00356889Phase 2Results posted
• Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell CarcinomaCompletedNCT00353301Phase 2Results posted
• Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung CancerTerminatedNCT00351039Phase 1/2Results posted
• A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic CancerTerminatedNCT00336700Phase 2Results posted
• Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaCompletedNCT00335764Phase 1/2Results posted
• Phase I/II Study of Chemoprevention With EGFR and COX-2 InhibitorCompletedNCT00314262Phase 1/2Results posted
• ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)CompletedNCT00313560Phase 2Results posted
• Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal CancerCompletedNCT00307736Phase 1/2Results posted
• Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)CompletedNCT00304278Phase 2Results posted
• Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic AstrocytomaCompletedNCT00301418Phase 1/2Results posted
• Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung CancerCompletedNCT00287989Phase 2Results posted
• Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular CarcinomaCompletedNCT00287222Phase 2Results posted
• Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLCCompletedNCT00283244Phase 2Results posted
• Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung CancerTerminatedNCT00281021Phase 2Results posted
• Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung CancerCompletedNCT00280150Phase 1/2Results posted
• Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung CancerCompletedNCT00278148Phase 1/2Results posted
• Individualized Drug Treatment for Treating Patients With Pancreatic CancerTerminatedNCT00276744Phase 2Results posted
• Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate CancerCompletedNCT00272038Phase 2Results posted
• A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)CompletedNCT00257608Phase 3Results posted
• A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)TerminatedNCT00251589Phase 1/2Results posted
• Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By SurgeryCompletedNCT00242502Phase 2Results posted
• OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung CancerCompletedNCT00230126Phase 2Results posted
• Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus ErlotinibCompletedNCT00203424Phase 2Results posted
• Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell CarcinomaCompletedNCT00193258Phase 1/2Results posted
• Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain TumorsCompletedNCT00187486Phase 2Results posted
• Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00153803Phase 3Results posted
• Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck CancerCompletedNCT00140556Early Phase 1Results posted
• Erlotinib in Women With Previously Untreated Adenocarcinoma of the LungCompletedNCT00137839Phase 2Results posted
• Bevacizumab and Erlotinib Study in Advanced Ovarian CancerCompletedNCT00130520Phase 2Results posted
• Study of Tarceva and Targretin in Stage I-II Lung CancerCompletedNCT00125372Not applicableResults posted
• Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung CancerCompletedNCT00125359Phase 2Results posted
• Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed GliomaCompletedNCT00124657Phase 1/2Results posted
• Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung CancerTerminatedNCT00096265Phase 3Results posted
• Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic CancerCompletedNCT00091026Phase 2Results posted
• Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2CompletedNCT00085839Phase 2Results posted
• OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell CancerCompletedNCT00076310Phase 2Results posted
• S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath TumorCompletedNCT00068367Phase 2Results posted
• Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung CancerTerminatedNCT00063258Phase 2Results posted
• Erlotinib Plus Carboplatin and Paclitaxel in Ovarian CarcinomaCompletedNCT00059787Phase 2Results posted
• Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast CancerCompletedNCT00054275Phase 2Results posted
• Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast CancerCompletedNCT00054132Phase 2Results posted
• Erlotinib in Treating Patients With Advanced Kidney CancerCompletedNCT00045487Phase 2Results posted
• Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu OverexpressionCompletedNCT00033514Phase 1/2Results posted
• Brazilian Lung Immunotherapy StudyCompletedNCT05081674Phase 2
• The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
• A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditionsCompletedNCT04145570Phase 4
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.TerminatedNCT03460678Phase 4
• Carbon Ion Radiation Therapy for Locally Advanced Pancreatic CancerCompletedNCT03403049Phase 1
• Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownNCT03239015Phase 2
• A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)Status unknownNCT03126799Phase 2
• Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective StudyStatus unknownNCT03110484Phase 2
• Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard ChemotherapyCompletedNCT03086538Phase 2
• Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLCStatus unknownNCT03074864Phase 2/3
• Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLCTerminatedNCT02991651Phase 1
• Study of Ixazomib and Erlotinib in Solid TumorsCompletedNCT02942095Phase 1
• EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLCStatus unknownNCT02886195Phase 3
• Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell CarcinomaTerminatedNCT02775006Phase 3
• Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized StudyStatus unknownNCT02748707Phase 2
• Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic CancerStatus unknownNCT02737228Phase 1/2
• Pemetrexed and Erlotinib for Metastatic Colorectal CancerCompletedNCT02723578Phase 2
• Thoracal Radiotherapy and TarcevaTerminatedNCT02714530Phase 2
• Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid TumorsWithdrawnNCT02689336Phase 2
• Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II TrialStatus unknownNCT02655536Phase 2
• Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
• Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLCCompletedNCT02625168Phase 2
• IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain MetastasesTerminatedNCT02556593Phase 2
• A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET AmplificationTerminatedNCT02468661Phase 1
• Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung AdenocarcinomaStatus unknownNCT02399566Phase 4
• Multiple Treatments for Ebola Virus Disease (EVD)Status unknownNCT02380625Phase 1/2
• Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver MutationsWithdrawnNCT02277457Early Phase 1
• HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)Status unknownNCT02239952Not applicable
• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) EradicationStatus unknownNCT02233049Phase 2
• Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT02206763Phase 1
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruitingNCT02194738Not applicable
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)Active, not recruitingNCT02193282Phase 3
• A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFRTerminatedNCT02178397Phase 3
• Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic CancerCompletedNCT02154737Phase 1
• A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung AdenocarcinomaStatus unknownNCT02146118Phase 2

← Erlotinib overview